Literature DB >> 11786660

Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer.

M Sakamoto1, K Mikasa, T Majima, K Hamada, M Konishi, K Maeda, E Kita, N Narita.   

Abstract

We have previously reported that long-term treatment with clarithromycin (CAM) increased the median survival of patients with non-small cell lung cancer, and improved various clinical parameters in these patients. In the present study, CAM was administered to 33 patients with unresectable primary non-small cell lung cancer, who had received chemotherapy, radiotherapy or both (basic cancer therapy). Patients with clinical backgrounds matched to the CAM group, who did not receive CAM treatment, were included into this study as a control group (non-CAM group). CAM treatment was initiated 4 weeks after the basic cancer therapy. The non-CAM group did not receive a placebo. Before and after the 3-month treatment with CAM, body weight, serum levels of interleukin-6 (IL-6, a cytokine which, together with TNF-alpha, plays a crucial role in the development of cancer cachexia), total protein, albumin, cholinesterase and hemoglobin were measured for the evaluation of the patients' clinical status. There were no statistically significant differences in serum levels of IL-6 between the CAM group before the treatment and the non-CAM group. After 3 months of CAM treatment, serum levels of IL-6 significantly decreased. In contrast, body weight, cholinesterase, and hemoglobin increased to a significant extent. Among these four parameters, however, the decrease in serum IL-6 levels was only statistically correlated with the increase in body weight, but not with that in other parameters. Furthermore, CAM-treated patients whose serum IL-6 levels were decreased after 3 months of treatment survived longer: there was a statistically significant correlation between the decrease in serum IL-6 and survival time. In contrast, in the non-CAM group, these parameters did not change significantly during the study. These results suggest that CAM may reduce the progression of cancer-associated cachexia. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11786660     DOI: 10.1159/000048556

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  8 in total

Review 1.  Treatment of non-pain-related symptoms.

Authors:  Charles F von Gunten; Ellin Gafford
Journal:  Cancer J       Date:  2013 Sep-Oct       Impact factor: 3.360

2.  Intratumoral expression of macrophage migration inhibitory factor is correlated with serum C-reactive protein and interleukin-6 in patients with non-small cell lung cancer.

Authors:  Motoharu Hamatake; Ichiro Yoshino; Makiko Tomiyasu; Naoko Miura; Hiroshi Okazaki; Taro Ohba; Tomohiro Takenaka; Yoshihiko Maehara
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

3.  Repurposing Drugs in Oncology (ReDO)-clarithromycin as an anti-cancer agent.

Authors:  An Mt Van Nuffel; Vidula Sukhatme; Pan Pantziarka; Lydie Meheus; Vikas P Sukhatme; Gauthier Bouche
Journal:  Ecancermedicalscience       Date:  2015-02-24

4.  Cachexia research in Japan: facts and numbers on prevalence, incidence and clinical impact.

Authors:  Masaaki Konishi; Junichi Ishida; Jochen Springer; Stefan D Anker; Stephan von Haehling
Journal:  J Cachexia Sarcopenia Muscle       Date:  2016-04-12       Impact factor: 12.910

Review 5.  Inflammatory and Anti-Inflammatory Equilibrium, Proliferative and Antiproliferative Balance: The Role of Cytokines in Multiple Myeloma.

Authors:  Caterina Musolino; Alessandro Allegra; Vanessa Innao; Andrea Gaetano Allegra; Giovanni Pioggia; Sebastiano Gangemi
Journal:  Mediators Inflamm       Date:  2017-09-26       Impact factor: 4.711

Review 6.  Targeting the Gut Microbiota to Treat Cachexia.

Authors:  Laurence Genton; Julie Mareschal; Yannick Charretier; Vladimir Lazarevic; Laure B Bindels; Jacques Schrenzel
Journal:  Front Cell Infect Microbiol       Date:  2019-09-12       Impact factor: 5.293

7.  Clarithromycin synergizes with cisplatin to inhibit ovarian cancer growth in vitro and in vivo.

Authors:  Bo Zhou; Meng Xia; Bin Wang; Niresh Thapa; Lijuan Gan; Chaoyang Sun; Ensong Guo; Jia Huang; Yulan Lu; Hongbin Cai
Journal:  J Ovarian Res       Date:  2019-11-08       Impact factor: 4.234

8.  Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease.

Authors:  Alexander L Pukhalsky; Galina V Shmarina; Nikolai I Kapranov; Svetlana N Kokarovtseva; Daria Pukhalskaya; Natalia J Kashirskaja
Journal:  Mediators Inflamm       Date:  2004-04       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.